DUBLIN–(BUSINESS WIRE)–The “Oral Proteins and Peptides Market by Target Disease Indication, Type of Molecule, Technology Platforms, Biological Target, Mechanism of Action, Key Players, and Key Geographical Regions, 2022-2032” report has been added to ResearchAndMarkets.com’s offering.
This report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain.
Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides.
Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa (2020), Trulance (2017) and Linzess (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration associated with the oral delivery method has been demonstrated increase treatment adherence to as well as reduce the risk of non-compliance.
Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines.
In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.
Companies Mentioned
- 3P Biopharmaceuticals
- 7-Med Health Ventures
- 9 Meters Biopharma
- Aalto Scientific
- Abbott Laboratories
- AbbVie
- Abeona Therapeutics
- Abingworth
- ABL Venture Capital
- Abzena
- Access Pharmaceuticals
- ACES Pharma
- Acorn Biomedical
- ActoGeniX
- Adage Capital Management
- Adams Capital Management
- Adar Biotech
- Adcock Ingram
- Aegis Capital
- Aescap Venture
- Affilogic
- Affinity Life Sciences
- AIM ImmunoTech
- AIMM Therapeutics
- Ajinomoto Bio-Pharma Services
- Alaven Pharmaceutical
- Alba Therapeutics
- Albert Einstein Medical Center
- And Many More Companies!
Key Questions Answered
- Who are the key players involved in the development of oral protein / peptide therapeutics?
- Which technologies are leveraged the most by oral protein / peptide therapy developers?
- Who are the key opinion leaders in this domain?
- Which geographies are the most active in conducting clinical trials focused on oral protein / peptide therapeutics?
- Which companies have received the maximum funding for the development for oral protein / peptide therapeutics? Who are the most prominent investors?
- Which partnership models are commonly adopted by industry stakeholders in the development of oral protein / peptide therapeutics?
- Which organizations have filed the maximum number of patents in this field?
- How is the current and future market opportunity likely to be distributed across key market segments?
For more information about this report visit https://www.researchandmarkets.com/r/u8dnqk
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900